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Quadruple Valve Replacement for Carcinoid 
Heart Disease
Syed Saleem Mujtaba1, MD; Stephen Clark1, MD
Abstract
Introduction: Carcinoid heart disease most frequently 
involves the tricuspid or, more rarely, the pulmonary valve and 
presents with right heart failure as 5-HT is metabolized by the 
lung. Left-sided valve involvement is quite rare. We describe our 
experience of 3 patients presenting with heart failure secondary 
to carcinoid heart disease affecting all four cardiac valves. There 
are only four previous isolated case reports in the literature. 
Methods: All three patients underwent quadruple valve 
replacement during a single operation. Right ventricular outflow 
tract reconstruction with a pericardial patch was performed in 
all patients. For 24 hours prior to surgery, all patients received 
intravenous octreotide, which continued in intensive care for at 
least 24 hours. 
Results: Mean cross-clamp and bypass times were 175 (range 
164-197 minutes) and 210 (range 195-229 minutes) minutes, 
respectively. Mean intensive treatment unit (ITU) and inpatient 
stays were 2.3 (range 2-3 days) and 12 (range 9-16 days) days, 
respectively. One patient was reopened for bleeding 4 hours 
postoperatively from a ventricular pacing wire site. None 
required a permanent pacemaker postoperatively. There were 
no other complications in any patient. The quality of life was 
excellent at 6-16 months clinic follow-up as they were in NYHA 
1. Postoperative echocardiography showed no paravalvular leaks 
and well-functioning prostheses in all cases. 
Conclusion: Surgery to replace all four valves is feasible 
with excellent medium-term survival and a very low rate of 
complications. Patients with carcinoid heart disease should 
always be considered for surgery irrespective of the extent of 
valvular involvement. 
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INTRODUCTION
Carcinoid heart disease is a rare cause of intrinsic right 
heart valve disorders, leading to right heart failure. Left-sided 
heart valves involvement is occasional. Cardiac involvement in 
carcinoid disease generally results in tricuspid insufficiency and 
pulmonary stenosis. Carcinoid tumours are neuroendocrine 
malignancy. Ninety per cent of all carcinoid tumours are 
located in the gastrointestinal system, of which the most 
common sites are the appendix and terminal ileum[1]. Carcinoid 
tumours must be invasive or metastasise to produce carcinoid 




 = Computed tomography 
 = New York Heart Association
 = Patent foramen ovale 
syndrome, which is characterized by facial flushing, diarrhea, 
and bronchospasm. The incidence of carcinoid tumours is 
approximately 1 in 75,000 of the population[2], of whom about 
50% develop carcinoid syndrome. Once carcinoid syndrome has 
developed, approximately 50% of these patients will go on to 
develop carcinoid heart disease or Hedinger syndrome. 
METHODS
We describe our experience with 3 patients who underwent 
simultaneous quadruple valve replacement for carcinoid heart 
disease. Patients were in mid 50’s (mean 55.3, range 55-56 years, 
male=1, female=2). All had been diagnosed with a small bowel 
carcinoid tumour with liver metastases having initially presented 
with abdominal pain, flushing and dyspnoea [New York Heart 
Association (NYHA) functional class 3-4]. Computed tomography 
(CT) of the abdomen revealed multiple liver metastases and 
a small bowel mesenteric mass. A laparoscopic biopsy was 
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consistent with a low-grade carcinoid tumor. All had good 
medium-term estimated prognoses but were deteriorating 
rapidly due to congestive heart failure.
Examination of all patients revealed an elevated jugular 
venous pressure with prominent ‘V’ waves and bilateral pedal 
oedema. On auscultation, there were systolic murmurs over 
the apex and left fourth intercostal space. Early diastolic 
murmurs were present at the upper and lower left sternal edges. 
Echocardiography revealed advanced features of heart failure. 
All four cardiac valve leaflets were fixed, thickened, retracted 
and failed to coapt. There was at least moderate to severe 
regurgitation of all four valves (Figures 1 to 3), except in one 
patient who had mild tricuspid regurgitation but thickened fixed 
leaflets consistent with carcinoid involvement (Figures 4 to 6). A 
patent foramen ovale (PFO) was not found in any patient. The left 
ventricular function was preserved in two and moderate in the 
third patient (mean 50%, range 40-55%), while the right ventricle 
was dilated with preserved function. The coronary arteries were 
disease-free on angiography. Mean logistic EuroSCORE was 4.1 
(range 2.04-7.41).
Because of the severity of cardiac symptoms, given that 
there estimated life expectancy was more than two years and 
based on the course of their carcinoid disease, the patients were 
accepted for surgery. 
An intravenous infusion of octreotide (600 µg in 60 mL 0.9% 
saline) was commenced a day before surgery at a rate of 5 mL/h, 
delivering 50 µg/h octreotide. This continued during surgery and 
stopped 48 hours after the operation. Surgery was performed 
with the patient on aortobicaval cardiopulmonary bypass via 
a midline sternotomy. The patient’s systemic temperature was 
lowered to 32°C, with myocardial protection being achieved 
through antegrade cold blood cardioplegia, which was repeated 
every 30-45 minutes. All excised valves had a classical appearance 
characteristic of carcinoid heart disease (Figures 7 and 9). 
In two patients, the aortic and mitral valves were replaced 
with CarboMedics mechanical valves while the tricuspid 
and pulmonary valves were replaced with Perimount 
Magna bioprostheses (Figure 10). This permitted the use of a 
postoperative pulmonary artery flotation catheter and given the 
durability of bioprostheses in the right heart. In the third patient, 
all valves were replaced with Perimount Magna bioprostheses. 
Right ventricular outflow tract reconstruction (pulmonary 
augmentation) with a pericardial patch was performed in all 
patients. 
RESULTS
The mean cardiopulmonary bypass time was 211 min (range 
195-229 min) and the cross-clamp time 179 min (range 164-
197 min). Patients were transferred to the intensive care unit 
in a hemodynamically stable condition, with a modest dose of 
adrenaline and noradrenaline, and all were extubated on the 
night of their surgery. They were temporarily paced for four 
days with subsequent recovery of their intrinsic sinus rhythm 
and the pacing was discontinued. None required a permanent 
pacemaker. None had any other postoperative complications 
what so ever, except for one patient who required re-exploration 
4 hours postoperatively for bleeding from a right ventricular 
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Fig. 1 - Transesophageal echocardiogram showing severe mitral 
regurgitation.
Fig. 2 - Transesophageal echocardiogram showing massive aortic 
regurgitation.
Fig. 3 - Transthoracic echocardiogram showing torrential 
pulmonary regurgitation.
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Fig. 4 - Transesophageal echocardiogram showing thickened 
aortic valve leaflets.
Fig. 5 - Transesophageal echocardiogram showing severely 
thickened mitral valve leaflets.
Fig. 6 - Transthoracic echocardiogram showing severely thickened 
tricuspid valve leaflets.
Fig. 7 - Histology slide of carcinoid aortic valve.
Fig. 8 - Histology slide of carcinoid mitral valve.
Fig. 9 - Histology slide of carcinoid pulmonary valve.
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temporary pacemaker site. All were discharged home in a stable 
condition.
The mean intensive care unit stay was 2 days while the mean 
hospital stay was 12 days (range 9-16) (Table 1). Postoperative 
echocardiography showed all prostheses were seated well with 
no paravalvular leaks. All excised valves had pathologic findings 
consistent with carcinoid heart disease. They were followed for 
6-16 months (mean 12 months) in the outpatient clinic and all 
were NYHA class 1. One patient went on to ileal carcinoid tumour 
and hepatic metastasis resection.  
DISCUSSION
The cardiac manifestations are caused by 5-hydroxytryptamine 
(5-HT or serotonin) released by the malignant cells rather than 
any direct metastatic involvement of the heart. Preferential 
right heart involvement is most likely related to inactivation of 
the vasoactive substances by the lungs. In 5-10% of cases with 
left-sided valvar pathology, one should suspect extensive liver 
metastases, bronchial carcinoid, or a patent foramen ovale[3,4].
Table 1. Outcomes of patients with carcinoid heart disease who underwent quadruple valve replacement.
Patient 1 2 3
Age (years) 56 55 55
Gender Male Female Female
NYHA preoperative 3 4 3
NYHA postoperative 1 1 1
Surgery August 2015 November 2015 August 2016
Follow-up (months) 16 14 6
PFO No No No
X-clamp (minutes) 177 197 164
Bypass (minutes) 209 229 195
Aortic regurgitation Moderate-severe Moderate-severe Severe
Valve implanted 23 mm CarboMedics 23 mm Perimount Magna 19 mm CarboMedics
Mitral regurgitation Moderate-severe Severe Severe
Valve implanted 27 mm CarboMedics 25 mm Perimount Magna 27 mm CarboMedics
Tricuspid regurgitation Severe Severe Mild
Valve implanted 29 mm Perimount Magna 25 mm Perimount Magna 25 mm Perimount Magna
Pulmonary regurgitation Severe Severe Moderate-severe
Valve implanted 23 mm Perimount Magna 21 mm Perimount Magna 23 mm Perimount Magna
EuroSCORE 4 7 3
Logistic EuroSCORE 2.86 7.41 2.04
Left ventricle Good (EF 55%) Moderate (EF 40%) Good (EF 55%)
Right ventricle Ventricle dilated Dilated Ventricle dilated
ICU stay (days) 2 2 3
Hospital stay (days) 9 11 16
Chest drain (mL) 2,200 250 250
EF=ejection fraction; ICU=intensive care unit; NYHA=New York Heart Association; PFO = patent foramen ovale; X-clamp=aortic cross-clamp
Fig. 10 - Chest X-ray showing all four replaced valves.
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months after implantation, being the result of intractable high 
levels of NET vasoactive products inducing carcinoid plaque 
reformation[16-18]. Evidence for this, however, is relatively weak. 
On the other hand, the use of mechanical prosthesis requires 
life-time anticoagulation in these patients who have an already 
increased risk of bleeding due to hepatic dysfunction. In 
addition, the risk of mechanical tricuspid mechanical prosthesis 
thrombosis is approximately 4% per year[19]. Therefore, choice of 
the prosthesis should be tailored to the individual patient risk of 
bleeding, life expectancy, and future interventions. An additional 
consideration is the ability to insert a pulmonary artery flotation 
catheter postoperatively through a biological prosthesis to 
assist management especially after multivalve replacements in 
patients with pre-existing cardiac failure. Although surgical valve 
replacement is the gold standard treatment for symptomatic 
carcinoid heart valve disease, transcatheter pulmonary valve 
replacement should be considered as an alternative approach 
in high-risk candidates[20]. Percutaneous valve implantation in 
the pulmonary and in the inferior vena cava positions may offer 
minimally invasive alternative in the high-risk patients[21]. 
Mabvuure et al.[22] cautiously concluded that biological 
valves have an acceptable lifespan in patients with carcinoid 
syndrome and that the process of valve destruction seen in 
carcinoid patients does not continue to a significant level in 
the bioprosthesis. Although there opinion lacks, any direct 
comparative trial or higher-level evidence is predominantly 
based on case reports.
The present article highlights three cases of simultaneous 
quadruple valve replacement in for carcinoid heart disease, and 
further supports the possibility of not only successful quadruple 
valve replacement, but also an excellent postoperative outcome 
for patients with a reasonable life expectancy and well-controlled 
disease. Complications are few and management is aided by 
perioperative octreotide infusion.
CONCLUSION
Quadruple valve replacement is an acceptable option for 
patients with a good prognosis and symptomatic carcinoid 
heart disease affecting all four heart valves. An experienced 
medical, surgical, and anesthetic team approach to the patient 
with carcinoid heart disease is critical to provide state-of-the-
art management for these patients. Excellent outcomes can be 
achieved with low risk of complications.
Circulating serotonin levels are more than twofold higher and 
urine levels of the serotonin metabolite 5-HIAA are almost fourfold 
higher in the carcinoid heart disease patients compared with the 
noncardiac group. Elevated serum serotonin is 100% sensitive, but 
only 46% specific for carcinoid heart disease[5].
Patients with carcinoid syndrome should be treated in 
specialized centers by a multidisciplinary team, including 
oncologists, cardiologists, pathologists, and surgeons[6]. Without 
intervention, patients may develop progressively worsening 
symptomatic right heart failure. Life expectancy is significantly 
reduced as a result when prognosis otherwise from the carcinoid 
tumour may be good in the medium- to long-term. The Mayo 
Clinic showed a mean life expectancy of 1.6 years for those with 
the cardiac disease compared with 4.6 years for those without 
cardiac disease in patients with metastatic midgut carcinoid 
tumours[7].
Medical management is directed by reduction of symptoms 
caused by right-sided heart failure and includes fluid and 
electrolyte management, diuresis, and enhancing cardiac 
function. This can be achieved with the use of digoxin, loop and 
thiazide diuretics, salt and fluid restrictions, and continuation 
of somatostatin analogues[4]. Treatment with octreotide gives 
rise to both directly observable clinical benefit and measurable 
biochemical improvement. About 70% of patients obtain 
symptomatic relief from diarrhea and flushing, showing a 
decrease in measurable 5-HIAA urinary secretion and serum 
5-HT concentrations[8]. There is some evidence that the use of 
leucocyte interferon-alpha controls the secretion of tumour 
products, can produce a notable reduction in tumour size with 
evidence of survival benefit. Unfortunately, however, there are no 
data to suggest that either interferon or octreotide can cause any 
regression of the cardiac damage caused by carcinoid disease. 
Cytotoxic chemotherapy is given for extensive disease and dual 
endothelin receptor antagonist like bosentan prevents valvular 
and mural fibrosis and improve heart function[9].
Cardiac surgery offers marked symptomatic improvement of 
>1 New York Heart Association class after valve replacement[10,11]. 
There also may be survival benefit with cardiac surgery, 
although this is difficult to prove, given the other morbidities in 
this patient group. The surgical indications of carcinoid heart 
disease are symptomatic right ventricular failure, severe valvular 
dysfunction and systemic venous pressure elevation[12]. Surgery 
is contraindicated in end-stage metastatic disease, patients with 
poorly controlled carcinoid symptoms despite octreotide therapy, 
or hepatic dearterialization[13]. Median survival after cardiac valve 
replacement varies between 6 and 11 years[14]. The improved 
survival of patients with congestive cardiac failure in recent years 
may reflect the increasing surgical expertise in this field and better 
perioperative management of the patient with octreotide[6].
More controversial is the choice of the valve prosthesis. 
Problems for homograft use for pulmonary valve replacement are 
homograft constriction, homograft calcification and homograft 
plaque deposition. In most cases, the involvement of valve 
leaflets is too extensive to allow surgery for commissurotomy 
or valvotomy, and pulmonary valvectomy surgery is required[15]. 
On the one hand, biological prosthetic valve degeneration with 
valve allograft failure has been reported to occur as early as 3 
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